After natalizumab: what are the options?

 

REPORT FROM THE 67TH AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING – WASHINGTON DC, APRIL 18-25, 2015 – It is well established that the risk of progressive multifocal leukoencephalopathy (PML) is substantially increased after 24 infusions of natalizumab. What is less well known is how best to manage patients following natalizumab discontinuation, and several studies at AAN have examined different switching options. 

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page